Cavalier Investments LLC Boosts Stock Position in Novo Nordisk A/S $NVO

Cavalier Investments LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 81.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,537 shares of the company’s stock after acquiring an additional 18,608 shares during the quarter. Cavalier Investments LLC’s holdings in Novo Nordisk A/S were worth $2,305,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Capital International Investors raised its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the period. Franklin Resources Inc. boosted its position in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares during the period. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after purchasing an additional 187,789 shares in the last quarter. Folketrygdfondet increased its stake in shares of Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after purchasing an additional 117,370 shares in the last quarter. Finally, Sustainable Growth Advisers LP raised its position in shares of Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after purchasing an additional 649,390 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on NVO shares. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a report on Tuesday, March 3rd. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $49.93.

Novo Nordisk A/S Trading Down 0.1%

Shares of NVO stock opened at $37.99 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $169.61 billion, a price-to-earnings ratio of 10.95 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $82.57. The stock’s 50-day moving average price is $50.14 and its 200-day moving average price is $51.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 52.74%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.